Radiotherapy plus chemotherapy in muscle-invasive bladder cancer [1]
Journal
New England Journal of Medicine
Journal Volume
367
Journal Volume
367
Journal Issue
4
Journal Issue
4
Pages
379-381
Start Page
379; author reply 380-381
Date Issued
2012
Author(s)
Abstract
To the Editor: Results from the Bladder Cancer 2001 (BC2001) trial by James and colleagues (April 19 issue)1 suggest that synchronous administration of f luorouracil and mitomycin C with radiotherapy improved locoregional recurrencefree survival among patients with muscle-invasive bladder cancer. However, two essential points regarding patient demographic characteristics and outcomes were not reported. First, there were no data regarding the outcomes among patients with primary tumors that could not be completely resected. The completeness of surgical resection before definitive treatment could have a clinically significant impact on the outcome. Second, we wonder whether the combined methods of treatment reduced bladder capacity in a clinically significant way; this reduction could influence the quality of life in these patients. Shiu-Dong Chung, M.D.
SDGs
Other Subjects
fluorouracil; mitomycin C; antineoplastic agent; antineoplastic agent; bladder cancer; bladder capacity; cancer combination chemotherapy; cancer localization; cancer survival; chemoradiotherapy; clinical effectiveness; drug efficacy; human; letter; local recurrence free survival; muscle invasive bladder cancer; primary tumor; priority journal; quality of life; bladder tumor; female; male; note; bladder cancer; cancer control; cancer prognosis; cancer recurrence; cancer surgery; disease free survival; metastasis; muscle invasive bladder cancer; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Urinary Bladder Neoplasms
Publisher
Massachussetts Medical Society
Type
letter